EUCTR2005-003841-14-GB进行中（未招募）1 期
A pilot evaluation of the pharmacokinetic and safety characteristics of TMC114/ritonavir and TMC125 co-administered to HIV-1-infected subjects with limited treatment options - Pilot PK study of TMC114/Ritonavir and TMC125
St Stephens AIDS Trust0 个研究点目标入组 10 人开始时间: 2005年9月2日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 10
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •1. The ability to understand and sign a written informed consent form, prior to participation in any screening procedures and must be willing to comply with all study requirements.
- •2. Male or non-pregnant, non-lactating female, between 18 to 65 years, inclusive.
- •3. Documented HIV-1 infection and detectable plasma viral load at the screening visit.
- •4. Receiving a stable antiretroviral regimen (including three or more drugs) for at least 12 weeks before screening.
- •5. Subject with documented failure to at least three classes of available antiretroviral agents.
- •6. Female subjects who are heterosexually active and of childbearing potential (i.e., not surgically sterile or at least two years post menopausal) must practice contraception as follows from screening through completion of the study including 30 days following last dose of study drug:
- •-barrier contraceptives (condom, diaphragm with spermicide)
- •-oral, implant or injectable hormonal contraceptive PLUS a barrier contraceptive
- •IUD PLUS a barrier contraceptive (or a partner who has been vasectomized for at least six months).
- •7. Female subjects of childbearing potential must have a negative serum pregnancy test.
- •8. Male subjects who are heterosexually active must use two forms of barrier contraception (e.g., condom with spermicide) during heterosexual intercourse, from screening through completion of the study including 30 days following last dose of study drug.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Any serious or active medical or psychiatric illness which, in the opinion of the Investigator, would interfere with subject treatment, assessment, or compliance with the protocol. This would include any active clinically significant renal, cardiac, hepatic, pulmonary, vascular, metabolic (thyroid disorders, adrenal disease), immunodeficiency disorders, active infection, malignancy, and any currently active AIDS defining illness (according to the CDC Classification System for HIV infection 1993).
- •2. Clinically relevant alcohol or drug use (positive urine drug screen) or history of alcohol or drug use considered by the Investigator to be sufficient to hinder compliance with treatment, follow-up procedures or evaluation of adverse events. Smoking is permitted, but tobacco intake should remain consistent throughout the study.
- •3. Any medication taken listed in Section 6.2 (Prior and Concomitant Therapy) including over-the-counter medications and herbal products within 14 days of commencing study drug dosing. When a concomitant medication is necessary, this will be reviewed by the Investigator and if not contraindicated, may be continued at the same dose and frequency during the study period.
- •4. Previously demonstrated clinically significant allergy or hypersensitivity to any of the excipients of the investigational medication administered in this trial.
- •5. Positive drug screening at two consecutive drug screening (a positive drug screening will be repeated between screening and day 1). The drug screening involves analysis for amphetamine, barbiturates, benzodiazepines, cocaine, and opioids (patients with a positive drug screening for cannabinoids will be allowed in the study).
- •6. Subjects with clinical or laboratory evidence of significantly decreased hepatic function or decompensation, irrespective of liver enzyme levels.
- •Note: subjects co-infected with chronic hepatitis B or C will be allowed to enter the trial if their condition is clinically stable, and are not expected to require treatment during the study period and have transaminase levels = 3 x ULN. Subjects diagnosed with aute hepatitis A at screening will not be allowed in the trial.
- •7. ALT and/or AST > 5 x ULN.
- •8. Subjects with laboratories abnormalities of grade 3 or 4 as defined by the DAIDS grading scheme (Appendix 5), with the exception of:
- •-subjects with pre-existing diabetes or asymptomatic glucose elevations of grade 3 or 4
- •-subjects with asymptomatic triglyceride or cholesterol elevations grade 4
研究者
相似试验
进行中（未招募）
不适用
A Phase 1B Study of the Safety and Pharmacokinetics of Ritonavir-Boosted Elvitegravir (GS-9137/r) Plus a Background Regimen (BR) in HIV-1 Infected, Antiretroviral Treatment-Experienced AdolescentsEUCTR2008-003917-29-GBGilead Sciences Incorporated24
尚未招募
2 期
A Clinical pilot study to evaluate effect of Nano Kanchanara Twak extract Capsule (Ayurvedic Medicine) in Hypothyroidism patientsCTRI/2022/05/042402Dean Faculty Of Ayurved
已完成
1 期
A phase I study to assess the pharmacokinetics of a single dose of a slow-release solid injection of EPT1647 in healthy male volunteers/AHealthy male volunteersOther -ACTRN12605000782639Epitan Limited6
招募中
不适用
A phase I study to evaluate the pharmacokinetic interactions and safety between Amlodipine/Valsartan combination tablet and Rosuvastatin in healthy adult volunteersDiseases of the circulatory systemKCT0001660Kyung Dong Pharmaceutical57
已完成
1 期
A Phase 1 Study of Olorofim in Healthy Japanese and Caucasian ParticipantsHealthy adult participantsJPRN-jRCT2031230016agata Tsutae24